Table 3.
Baseline characteristics.
| Study name | GLOBAL leaders | SMART CHOICE | STOPDAPT-2 | TWILIGHT* | TICO | MASTER DAPT | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Procedure | Complex PCI | Non-complex PCI | Complex PCI | Non-complex PCI | Complex PCI | Non-complex PCI | Complex PCI | Non-complex PCI | High-ischemic ACS | Non-high-ischemic ACS | Complex PCI | Non-complex PCI | ||||||||||
| Treatment | P2Y12i | DAPT | P2Y12i | DAPT | P2Y12i | DAPT | P2Y12i | DAPT | P2Y12i | DAPT | P2Y12i | DAPT | P2Y12i | DAPT | P2Y12i | DAPT | P2Y12i | DAPT | P2Y12i | DAPT | ||
| Number | 2283 | 2287 | 5434 | 5446 | 260 | 238 | 1235 | 1260 | 245 | 264 | 1255 | 1245 | 2342 | 4777 | 735 | 738 | 792 | 791 | 588 | 608 | 1707 | 1676 |
| Age, year | 65.3 (10.3) | 65.2 (10.1) | 64.2 (10.3) | 64.3 (10.3) | 64.7 (10.5) | 64 (10.9) | 64.6 (10.8) | 64.4 (10.6) | 69.2 (9.8) | 69.8 (10.3) | 68 (11.1) | 68.9 (10.5) | 66 (10.4) | 64.7 (10.3) | 62.9 (10.3) | 63 (10.6) | 58.7 (10.8) | 59.4 (10.6) | 76.51 (8.17) | 76.78 (8.3) | 75.98 (8.88) | 75.66 (8.92) |
| BMI, kg/m2 | 28 (4.4) | 28.1 (4.6) | 28.2 (4.6) | 28.2 (4.6) | 24.6 (3.3) | 24.8 (2.9) | 24.5 (3.4) | 24.7 (3.2) | 24.3 (3.1) | 24.6 (3.7) | 24.4 (3.6) | 24.2 (3.5) | 28.1 (5.3) | 28.8 (5.7) | 24.9 (3) | 25 (3.3) | 24.9 (3.2) | 24.8 (3.3) | 27.56 (4.61) | 27.58 (4.62) | 27.15 (4.7) | 27.39 (4.79) |
| Female | 21.8 | 20.9 | 24.2 | 24.2 | 26.5 | 22.3 | 27.4 | 26.5 | 19.8 | 20.8 | 21.6 | 24.1 | 21.3 | 25.1 | 23.8 | 22.5 | 18.7 | 17.6 | 18.7 | 29.6 | 31.4 | 31.2 |
| Diabetes mellitus | 27.5 | 25.1 | 24.7 | 24.6 | 45.8 | 41.6 | 36.6 | 36 | 45.3 | 50 | 37.8 | 35.5 | 37 | 36.7 | 56.9 | 56.5 | 0 | 0 | 34.4 | 33.4 | 32.3 | 34.7 |
| Current smoking | 26.9 | 26.5 | 25.4 | 26.4 | 25.8 | 25.2 | 29 | 24.4 | 22.9 | 20.8 | 27.3 | 20.6 | 20.6 | 22.3 | N.A | N.A | N.A | N.A | 8 | 6.4 | 10.8 | 8.7 |
| Hypertension | 74.5 | 73 | 73.5 | 73.4 | 68.1 | 68.5 | 60.3 | 60 | 75.9 | 76.5 | 73.2 | 73.4 | 71.2 | 73 | 60 | 60.8 | 40.3 | 42 | 80.4 | 77 | 75.7 | 78.7 |
| Dyslipidemia | 69.8 | 71.2 | 69.2 | 69.6 | 44.2 | 45 | 45.3 | 45.7 | 78 | 80.3 | 73.7 | 73.6 | 58.2 | 61.6 | 63.7 | 62.1 | 57.6 | 58.7 | 71.4 | 66.3 | 65.7 | 68.7 |
| CKD (eGFR < 60) | 14.1 | 14 | 13.8 | 13.3 | 6.2 | 5 | 2.3 | 3.3 | 45.3 | 42 | 39.2 | 40.1 | 18.1 | 16.1 | 39.7 | 44.4 | 0 | 0 | 22.3 | 20.1 | 16.8 | 20 |
| Previous MI | 20.9 | 21.8 | 23.5 | 24.1 | 3.5 | 3.8 | 4.3 | 4.4 | 18.4 | 17.1 | 12.9 | 12.4 | 28.7 | 28.6 | 4.5 | 4.3 | 3.9 | 2.1 | 21.1 | 23.8 | 18.2 | 17 |
| ACS | 48.6 | 48.6 | 46.4 | 46.2 | 54.6 | 61.3 | 58.9 | 57.6 | 34.3 | 30.3 | 38.3 | 40.4 | 63.6 | 65.4 | 100 | 100 | 100 | 100 | 48.1 | 47.3 | 49.5 | 47.4 |
Data are expressed as mean (standard deviation) or percentage (%).
ACS acute coronary syndrome, BMI body mass index, CKD chronic kidney disease, DAPT dual antiplatelet therapy, MI myocardial infarction, P2Y12i P2Y12 inhibitor, N.A. not available.
*The report from the TWILIGHT did not provide the data stratified by treatment arm.
†Only in the TICO trial, patients were divided into high-ischemic ACS vs. non-high-ischemic ACS. The definition of high-ischemic ACS included not only complex PCI but also diabetes mellitus and chronic kidney disease.